RE:RE:RE:Conference call ?LongTerm3 wrote: 23 new areas this year so far. In January they predicted 25 for the whole year. VMD is ahead of schedule.
Staffing, Sleep, and Oxygen doing good. M and A moving forward, in coming quarters
Estimated rate increase of 8 percent for inflation in January.
Lower cost for supplies.
67 percent vents.
Patient count over 9,100 Revenue almost 36 million. Both are gaining.
Overall what is not to like about these financial numbers released for the 3rd quarter. Viemed is firing on all cylinders during tough inflationary times as well as economic constraints. Yes SG and A expenses are up again modestly, however that is to be expected with a growing company along with rising costs for just about everything. Todd provided a good explanation to this question.
Reading between the lines it sounds like the company may be close to announcing an acquisition, I was a little surprised at Hoyt's comment that some of their targets have been on the radar for the past 2 years. It would appear that the timing and price to acquire is much more favorable to Viemeds terms.
Hoyt also mentioned making more progress with the VA program, which as most here know has been quite slow to develope. A little surprised that no analyst asked any questions in this regard. They continue to buy back shares and can purchase roughly another 300,000 shares under the current NCIB. Brooks Oneil asked if the company would consider a new NCIB, I believe Todd mentioned keeping some dry powder for acquisitions in the future. This comment suggests that an acquisition could be close, however that is strictly my opinion.
Forecasted numbers for Q4 look really solid, again reading between the lines it would not surprise me if they came in on the higher end, perhaps even beating the guidance as long as Covid stays under control. Overall another good CC, short and to the point.
The only negative here is these darn markets, still very little trading interest.